Brest

• A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patie … Ended recruitment
  2022-501493-19-00 5 2023-02-20 metastatic Castration-Resistant Prostate Cancer (mCRPC)
• DARIUS : A randomized non-comparative phase II multicentric trial on short term DARolutamide (ODM-201) concomitant to radiation therapy for … Ended recruitment
  2023-509494-23-00 4 2023-02-20 Adult patients with intermediate unfavorable risk prostate cancer as p
• Impact of a treatment with angiotensin receptor blocker on outcome after acute kidney injury in patients discharged from the ICU “START-or-N … Ended recruitment
  2024-515845-40-00 5 2022-11-22 Acute kidney injury
• RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutane … Ended recruitment
  2024-516168-27-00 5 2022-11-10 Adult patients with persistent or chronic immune thrombocytopenia
• Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended recruitment
  2024-514480-26-00 4 2022-10-12 Post-menopausal women with localized luminal A breast cancer and consi
• SPLEMENGO - Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies amo … Ended recruitment
  2024-513649-35-00 5 2022-09-15 Asplenia
• A safety and efficacy study of treatment combinations with and without chemotherapy in adult patients with advanced upper gastrointestinal t … Ended recruitment
  2024-511917-40-00 4 2022-09-13 Advanced Upper Gastrointestinal Tract Malignancies
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable … Ended recruitment
  2023-504195-14-00 5 2022-08-31 PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea … Ended recruitment
  2024-514630-21-00 4 2022-08-11 HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
• Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended recruitment
  2024-511068-10-00 5 2022-08-04 Sjögren’s Syndrome
• A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance … Ended recruitment
  2023-504996-26-00 5 2022-07-21 Metastatic Castration Resistant Prostate Cancer (mCRPC)
• A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended recruitment
  2023-510019-20-00 5 2022-07-13 Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis
• Avalglucosidase alfa French post-trial access for participants with Pompe disease Ended recruitment
  2024-514773-22-00 6 2022-07-11 Glycogen storage disease type II
• This study is to understand how well an investigational drug (called Napabucasin) works when given in combination with chemotherapy treatmen … Ended recruitment
  2024-518205-17-00 10 2022-05-27 Histologically or cytologically confirmed advanced pancreatic adenocar
• This study is to understand how well an investigational drug (called Napabucasin) works when given in combination with a chemotherapy treatm … Ended recruitment
  2024-518204-50-00 5 2022-04-25 Histologically confirmed adenocarcinoma of the colon or rectum that is
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and … Ended recruitment
  2024-516403-16-00 5 2022-04-07 Adult patients with immune thrombocytopenia (ITP) with mild to severe
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer Ended recruitment
  2023-506771-10-00 5 2022-03-11 Breast Neoplasm, Neoplasm Metastasis
• A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer Ended recruitment
  2023-509406-30-00 10 2022-01-24 Patients with HER2-overexpressing advanced or metastatic gastric or ga
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus (ALLEGORY) Ended recruitment
  2023-504774-38-00 5 2021-11-04 Systemic Lupus Erythematosus (SLE)
• A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas … Ended recruitment
  2023-510319-20-00 5 2021-10-21 Gastroesophageal Adenocarcinoma (GEA)
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended recruitment
  2023-503990-39-00 5 2021-09-30 Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
• Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended recruitment
  2024-510809-28-00 5 2021-09-27 Metastatic Castration-sensitive Prostate Cancer

Showing 337–360 of 478 trials